A Talk with Jacob Glanville: Computational Immunology vs COVID-19

Mar 26 2020

Moderator:

Echo Hindle-Yang, CEO at MSQ

Invited guests:

• Dr. Jacob Glanville, CEO and Co-founder at Distributed Bio

• Dr. Shawn Shi, Venture Partner at MSQ

About Distributed Bio:

The company’s mission is to create breakthrough technologies to drug previously challenging targets (GPCRs, ion channels, pMHC complexes, condition-specific binders, anti-idiotypes, and broadly neutralizing viral epitopes). In monoclonal therapeutics, the integration of computational immunology, bioengineering and robotics has enabled the company to create a pipeline of molecules with unprecedented biophysical properties, while also supporting all of the partners with thousands of high affinity developable antibodies against any drug target of interest. In vaccine science, the company’s Centivax technology is producing broad-spectrum vaccines against rapidly mutating pathogens like influenza and HIV.